Irinotecan and gemcitabine in patients with solid tumors: phase I trial.

Caio Max Rocha Lima, Swan Swan Leong, Carol A. Sherman, Joshua A. Perkel, Terri Putman, Ahmad R. Safa, Mark R. Green

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Using a day 1 and 8, every-3-week schedule, our purpose was to determine the maximum tolerated dose of irinotecan (CPT-11, Camptosar) that can be administered immediately after gemcitabine (Gemzar) at a dose of 1,000 mg/m2 IV. In this phase I trial, the maximum tolerated dose was defined as the dose level immediately below the level in which two of the first three patients in any cohort, or at least two of six patients in any expanded cohort, experienced dose-limiting toxicity. Dose-limiting toxicity pertained only to toxicity during the first cycle of treatment. Escalation of irinotecan was planned in groups of three patients, with three additional patients added at the first indication of dose-limiting toxicity. A total of 19 patients have been enrolled. Grade 4 diarrhea was the dose-limiting toxicity at the irinotecan dose of 115 mg/m2. Hematologic toxicity was not dose limiting. Three patients required canceling of the day 8 dose due to grade 3 myelosuppression. Three patients, two with pancreatic cancer and one with metastatic carcinoma of unknown primary, had a partial response. The maximum tolerated dose of irinotecan in this combination was 100 mg/m2/dose. The dose-limiting toxicity was diarrhea. The maximum tolerated dose is the recommended starting dose for phase II studies.

Original languageEnglish (US)
Pages (from-to)19-24
Number of pages6
JournalOncology (Williston Park, N.Y.)
Issue number5 Suppl 5
StatePublished - May 2002

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Irinotecan and gemcitabine in patients with solid tumors: phase I trial.'. Together they form a unique fingerprint.

Cite this